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Abstract: Background: Video-assisted thoracoscopic surgery (VATS) is widely used for the treatment
of empyema. We evaluated clinical symptoms, laboratory examinations, and thoracentesis to assess
patients in the emergency department (ED) with empyema thoracis, undergoing VATS to identify
predictors of adverse outcomes. Methods: This retrospective study was conducted by reviewing
records of ED patients with pleural empyema admitted for VATS from January 2007 to June 2014.
Demographic data, clinical symptoms, and laboratory examinations were compared for survivors
(Group I) and non-survivors (Group II). Logistic regression analysis was used to identify parameters
related to postoperative mortality. Results: From 380 patients, 7.6% (n = 29) died postoperatively.
Survivors and non-survivors exhibited differences in age, gender, presence of cough, dyspnea,
chest pain, empyema stage, cerebrovascular disease, malignancy, the glucose level of pleural fluid,
serum hemoglobin, platelet count, blood urea nitrogen, and potassium levels. The logistic analysis
demonstrated that the most significant factor related to the postoperative morbidity is chest pain (p = 0.018).
Conclusions: VATS could be a safe option for pediatric and geriatric patients. Age does not appear to
affect postoperative mortality. A high degree of awareness is essential for perioperative management and
early surgical treatment when ED patients present with the clinical symptom of chest pain.
Keywords: pneumonia; pleural empyema; chest pain; video-assisted thoracoscopic surgery;
emergency department; mortality
1. Introduction
Empyema thoracis is a collection of purulent fluid in the pleural space that mainly occurs with
pneumonia or secondary to chest trauma/surgery. Approximately half of the patients with pneumonia
develop pleural effusion, and 5–10% of patients may develop empyema thoracis after antibiotic
treatment [1]. It evolves from stage I (exudative), through stage II (fibrinopurulent), to stage III
(organized) for 3 to 6 weeks. Patients may have a fever, chest pain, and cough in the early stage,
whereas dyspnea may occur in the late stage. Treatment includes antibiotics, chest tube drainage,
surgical intervention with video-assisted thoracoscopic surgery (VATS), or open thoracotomy. However,
empyema thoracis is still a common problem, with high morbidity and mortality rates as a result
of suboptimal management [2]. Despite the use of antibiotics and different pneumococcal vaccines
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in clinical care, and improvement of the minimally invasive surgical techniques, empyema remains
the most common complication of pneumonia with a reported mortality rate between 10% and
20% [3]. Recent consensus guidelines show that the use of a chest tube as the first-line treatment
still needs further examination [4,5]. A cohort study in 2018 characterized the higher readmission
and reintervention rates in patients with thoracic empyema treated with chest tubes, and suggested
earlier surgical intervention [5]. Adequate treatment of thoracic empyema is stage-dependent, and
surgical intervention will be considered when antibiotic therapy and fluid drainage do not achieve
infection control successfully, along with good re-expansion of the lung [6]. Since the progression of
thoracic empyema is fluent, stratification by stage and treatment depend on the surgeon’s experience
and judgment. Although a systematic review demonstrated that treatment with VATS had superior
outcomes for pleural empyema, even as the first-line management [5,7], no consensus currently exists
about the timing for choosing VATS for the initial treatment. This study focused on patients presenting
to the emergency department (ED) with suspected empyema thoracis. Knowing the risks for death
related to treatment with VATS may enable surgeons to optimize therapeutic strategies for definitive
surgical management to avoid postoperative complications, and even to reduce mortality.
2. Material and Methods
During the study period (January 2007 to June 2014), a total of 380 patients presenting to our ED
with empyema thoracis were admitted for further evaluation and treatment. These patients received
immediate, detailed clinical and serum examinations. Before diagnostic thoracentesis, the disease
status was assessed via chest X-ray or computed tomography (CT). Patients were prescribed empiric
broad-spectrum intravenous antibiotics for the suspicion of thoracic empyema. Surgical intervention
with VATS was indicated in the presence of persistent fever, residual fluid after drainage, sepsis,
and worsening of the patient’s status with septations or loculations. All patients were operated on
under general anesthesia with the two- or three-portal procedure, based on the CT scan findings.
The process is described as follows. The first port was created at the site with pronounced collection.
Once the pleural cavity was entered, contents were suctioned, and other ports were created under
visual observation to avoid injury to the lung parenchyma. Instruments could be used between the
camera and working ports, and no rib retraction was applied in these patients. A specimen was
collected for microbiological tests, and inflammatory peel was stripped using both sharp and blunt
dissection. After completion of debridement, chest wall bleeding was resolved with electrocautery,
and the status of the affected lung and its expansion was assessed. At the end of the procedure,
one or two chest tubes were inserted under thoracoscopic visualization. Patients were discharged
after removal of the chest tube, with pleural drainage of less than 200 mL per day and completion of
intravenous antibiotics.
Patients who initially presented to the ED with septic shock, ventilator dependence and
cardiopulmonary distress, those lost to follow-up, and children with immunodeficiency and cerebral
palsy associated with swallowing disorders were excluded from this study. Images were judged by a
radiologist during routine radiological assessment. Two thoracic surgeons reviewed these findings
and the corresponding images before surgical treatment. The images were classified as follows: stage I
referred to fluid accumulation without loculations; stage II had fibrinous septations with loculations
and the presence of pus; stage III had multiple loculations and entrapped the underlying lung [8].
For the study, patients were divided into two groups: survivors (Group I) or non-survivors (Group
II). The following data were collected for the analysis of risk factors of postoperative mortality: Age,
gender, current smoking, comorbidities (chronic obstructive pulmonary disease, hypertension, diabetes
mellitus, renal insufficiency, cerebrovascular disease and malignancy), clinical presentation (fever,
cough, dyspnea and chest pain), biological samples (blood and pleural effusion), duration of surgery
(time from skin incision to skin closure), and location and stage of empyema thoracis. The hospital’s
ethics committee granted the ethical approval for this study, and informed consent was waived due to
the retrospective study design.
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Statistical Analysis
Categorical variables were compared by using χ2 or Fisher’s exact analyses. Continuous variables
were compared by using Mann–Whitney U analysis. A multivariate logistic regression analysis was
performed to assess the association between the variables, with statistically significant differences
between the two groups. A two-sided p value < 0.05 was used as the criterion for statistical significance.
Statistical analyses were performed using SPSS software ver. 22.0 (IBM, Armonk, NY, USA).
3. Results
A total of 380 patients were included in the analysis: 287 (75.5%) males and 93 (24.5%) females.
Sixty-two percent were 18 to less than 65 years old, 33% were aged 65 and above, and 5% were less than
18 years old. The mean age was 55.4 ± 20.0 years. Twenty-nine (7.6%) patients died during the 30 days
following the operation. The demographic and clinical characteristics of the two groups are displayed
in Table 1. One hundred and ninety-one (50.3%) patients were current smokers. The most prevalent
comorbidity was hypertension (33.9%), followed by diabetes (21.3%), chronic obstructive pulmonary
disease (17.1%), cerebrovascular disease (10.3%), malignancy (7.9%), and chronic renal insufficiency
(5.8%). The common symptoms at ED were dyspnoea (45.3%), fever (45.0%), chest pain (35.3%), and
cough (35.0%). Two hundred and thirty (60.5%) patients had right-sided thoracic empyema, and 34
(8.9%) patients had stage III empyema. The average operating time was 125.1 ± 91.8 min. There were
significant differences in age (patients ≥65 y of age), gender, cerebrovascular disease, malignancy,
dyspnea, chest pain, cough, and stage of empyema thoracis between the two groups.
Table 1. Demographic data of patients.
Variables Group I: Survivors(n = 351)
Group II:
Non-Survivors (n = 29) p Value *
Age (years) 54.3 ± 20.1 68.8 ± 12.6 <0.001
<18 20 (100.0%) 0 (0.0%) 0.114
≥18 and <65 221 (94.44%) 13 (5.56%) 0.638
≥65 110 (87.30%) 16 (12.70%) 0.039
Gender 0.006
Male 272 (94.77%) 15 (5.23%)
Female 79 (84.95%) 14 (15.05%)
Current smoking 177 (92.6%) 14 (7.4%) 0.849
Comorbidity 0.178
Hypertension 119 (92.2%) 10 (7.8%) 1.000
Diabetes mellitus 71 (87.7%) 10 (12.3%) 0.096
Chronic obstructive
pulmonary disease 58 (89.2%) 7 (10.8%) 0.306
Cerebrovascular disease 32 (82.1%) 7 (17.9%) 0.020
Renal insufficiency 20 (90.9%) 2 (9.1%) 0.680
Malignancy 23 (76.7%) 7(23.3%) 0.004
Symptoms 0.552
Fever 163 (95.3%) 8 (4.7%) 0.054
Dyspnea 153 (89.0%) 19 (11.0%) 0.031
Chest pain 129 (96.3%) 5 (3.7%) 0.042
Cough 129 (97.0%) 4 (3.0%) 0.014
Location 0.316
Right 210 (91.3%) 20 (8.7%)




Operative time (mins) 125.4 ± 88.9 121.2 ± 123.3 0.813
* Significance level: p < 0.05.
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Table 2 shows data from laboratory examinations. A pathogen was identified in 90 out of 380
(23.7%) patients with thoracic empyema in the ED and 9 (31.0%) patients had a positive culture in Group
II: methicillin-resistant Staphylococcus aureus in five (55.6%), Staphylococcus aureus in three (33.3%), and
Klebsiella pneumonia in one (11.1%). However, there was no statistically significant difference between
the groups.
Table 2. Organisms identified from the pleural fluid.
Organisms Group I: Survivors(n = 351)
Group II:
Non-Survivors (n = 29) p Value *
Positive 81 (90.0%) 9 (10.0%) 0.326
Staphylococcus aureus 8 (72.7%) 3 (27.3%)
Methicillin-resistant Staphylococcus aureus 5 (50.0%) 5 (50.0%)
Klebsiella pneumoniae 18 (94.7%) 1 (5.3%)
Extended-spectrum beta-lactamase-producing
Klebsiella pneumoniae 1 (100.0%) 0 (0.0%)
Viridans streptococci 24 (100.0%) 0 (0.0%)
Mycobacteria tuberculosis 23 (100.0%) 0 (0.0%)
Pseudomonas aeruginosa 2 (100.0%) 0 (0.0%)
* Significance level: p < 0.05.
Table 3 shows the results of the diagnostic thoracentesis. The non-survivor group had a significantly
higher pleural glucose level (144 ± 121 vs. 79 ± 127 mg/dL; p = 0.041). No significant difference
between the groups was found in pH value, white cell count (WBC), and lactate dehydrogenase (LDH)
levels in the pleural fluid. Laboratory examination of the blood revealed that the hemoglobin level
and platelet count were significantly lower in non-survivors (hemoglobin: 9.60 ± 1.86 vs. 11.53 ± 2.23
g/dL, p = 0.001; platelets: 202.00 ± 131.91 vs. 294.11 ± 15.77 109/L, p = 0.017). Blood urea nitrogen
(BUN) and potassium levels were significantly higher in non-survivors (BUN: 32.50 ± 25.47 vs. 20.88 ±
21.77 mg/dL, p = 0.049; potassium: 4.10 ± 0.78 vs. 3.79 ± 0.55, p = 0.046). There was no significant
difference between groups in serum WBC, creatinine, and sodium levels. Multiple logistic regression
analysis was performed using the factors described in the previous sections. The results implied that
cerebrovascular disease (p = 0.001), chest pain (p = 0.018), and serum potassium level (p = 0.023) were
independent risk factors for mortality, as shown in Table 4.
Table 3. Pleural fluid and laboratory findings analysis.
Variables Group I: Survivors(n = 351)
Group II:
Non-Survivors (n = 29) p Value *
Pleural effusion
pH value 7.68 ± 0.59 7.79 ± 0.47 0.429
White cell count 9661 ± 25,886 31,909 ± 78,096 0.448
Glucose, mg/dL 79 ± 127 144 ± 121 0.041
Lactate dehydrogenase (LDH), units/L 1918 ± 3478 2000 ± 5805 0.927
Blood
White cell count 15,010 ± 10,391 13,261 ± 6,615 0.373
Hemoglobin, g/dL 11.53 ± 2.23 9.60 ± 1.86 0.001
Platelet counts, 109/L 294.11 ± 150.70 202.00 ± 131.91 0.017
Blood Urea Nitrogen, mg/dL 20.88 ± 21.77 32.50 ± 25.47 0.049
Creatinine, mg/dL 1.20 ± 1.23 1.67 ± 1.52 0.145
Sodium levels 134.58 ± 3.91 134.25 ± 5.53 0.759
Potassium levels 3.79 ± 0.55 4.10 ± 0.78 0.046
* Significance level: p < 0.05.
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Table 4. Logistic regression coefficients (beta) and odds ratio estimates from the multivariate logistic
regression models for factors affecting mortality.
Factors
Coefficient p Value * OR
95% Confidence Interval for B
B Std. Error Lower Bound Upper Bound
Cerebrovascular disease −0.341 0.085 0.001 0.74 –0.459 –0.122
Malignancy –0.205 0.082 0.051 0.82 –0.325 0.001
Chest Pain 0.240 0.056 0.018 1.23 0.024 0.249
Serum Potassium level –0.237 0.047 0.023 0.79 –0.201 –0.015
* Significance level: p < 0.05.
4. Discussion
The incidence of pleural empyema increased at a rate of 2.8% per year from 1987 to 2004, and a
twofold increase occurred in the United States [9,10]. Review articles also showed the incidence of
empyema ranging from 0.9 to 12.5 per 100,000 population among children aged <19 years in Utah
(USA) (1994–2007) and Australia (1998–2010), and was higher in those aged >65 years (3.5–4.8 per
100,000) than other adult age groups in 1996–2001 and 2006–2009 [11]. Likewise, the significant
increase in the incidence of adult empyema, mainly in young adults (aged 18–50 years), was from
7.6% in 1996–2001 to 14.9% in 2005–2011, and a 23% increase has been observed in Canada (ages 40–54
years) [12]. However, there was no improvement in mortality over the study period [3]. Empyema
thoracis remains challenging for thoracic surgeons, with a high mortality rate between 5.4% to 18.3% [5].
Cases are also seen in children with delayed referral to ED with persistent fever, cough, and several
courses of broad-spectrum antibiotics by community physicians. In this 7-year single-center cohort
study, we analyze the outcomes of patients presenting to the ED with symptoms and signs of empyema
thoracis. Although they had VATS treatment during hospitalization, 7.6% of those patients died within
30 days after surgery, in or out of the hospital. The mortality may be associated with inadequate source
control, underlying comorbidities, or delays in providing definitive therapy. Therefore, identification
of risk factors and early surgical intervention in pleural space infections may help improve overall
survival rates and reduce the burden on hospitals.
Age was the leading risk factor for mortality, with a rate of 16.1% among elderly patients (≥65
years) [10]. Immunity is different in older and younger persons, such that elderly individuals do not
respond to immune challenge as robustly as the young [13]. Older people may present with atypical
symptoms, particularly decreased severity of chest pain and fever than younger patients in the ED,
which makes the early diagnosis of thoracic empyema difficult [14]. Additionally, higher age and a
higher rate of comorbidities are related to functional decline, which possibly results in older patients
with thoracic empyema having higher mortality rates [15]. However, recent findings have shown that
multi-morbidity, rather than age, is the primary risk factor for a fatal outcome in all patients undergoing
surgical treatment for pleural empyema [3]. Besides, initial chest tube management has been reported
to have a higher failure rate, with the necessity of reintervention during hospitalization [5,16,17]. There
is no doubt that the advent of VATS has made it possible to treat early-stage empyema with less
morbidity. However, no evidence exists regarding the surgical approach (thoracotomy vs. VATS) for
stage III empyema [6,18]. Although management of chronic stage III empyema remains a challenge
for the thoracic surgeon, VATS has effectiveness in treating multiloculated and chronic empyema.
Our study indicated that comorbidity with cerebrovascular disease is related to mortality, whereas age
or empyema stage was not a risk factor for mortality. This may be the result of correct and targeted
antibiotic treatment, and improvement of minimally invasive surgical techniques in recent decades.
Clinical symptoms have been suggested as one of the means to estimate the stage of empyema,
as patients in empyema stage II and III may experience shortness of breath which is caused by
pleural adhesion and decreased expansion of the lung [7,19]. In our study, there was no statistical
significance in the symptoms of fever, cough, and dyspnea, but chest pain was the significant risk
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factor differentiating the two groups. This surprising risk factor may be induced by compression of the
intercostal nerves [20].
Evaluating and diagnosing through early identification of the microbial etiologies would guide
early targeted antimicrobial therapy and improve clinical outcomes [21]. Our data showed the
S. aureus and methicillin-resistant S. aureus were the most frequently identified pathogen in the
non-survivor group, which is in agreement with published data on the etiology of pleural empyema
undergoing surgical treatment [22–24]. It is important to note that Viridans streptococci and Mycobacteria
tuberculosis are the most common cause of empyema in the survivor group, which may be easily
overlooked. Viridans streptococci are most prevalent in the oral cavity and upper respiratory tract, and
are the main etiologic agents of empyema with a less frequent productive cough and more frequent
bed-ridden status [25,26]. Although uncommon, Viridans streptococci are emerging as a cause of
community-acquired respiratory tract infection, with an incidence of 3% to 15% in a few studies [26].
Tuberculous empyema has been reported in nearly 40% of thoracic empyema in India [27], and there is
an increasing incidence of Mycobacterium tuberculosis in the United Kingdom and elsewhere in Europe,
so it is imperative that all patients with empyema are routinely screened [21,28].
Through the laboratory analysis of blood and pleural fluid, it is possible to provide much
useful information for the cause of pleural effusions. A long observation period study in the United
Kingdom showed that multiple preoperative laboratory results were associated with early postoperative
mortality, without data regarding serum potassium [21]. Although the pleural glucose concentration,
serum hemoglobin, platelets, BUN, and potassium levels were significantly different in our study,
further logistic analysis showed only the serum potassium level was an independent risk factor for
postoperative mortality. Dyskalemia is a condition which occurs in patients with severe sepsis as a
result of inadequate drainage and inefficient control of infection.
The indication for and timing of surgical intervention in the management of empyema remains
controversial, especially in children. An important consideration to perform any surgical procedure is
to weigh the benefits against the risks in the appropriate patients, to improve overall outcomes. In this
study, we evaluated the possible risk factors of empyema thoracis treatment by VATS from the ED
patients’ records. Early surgical intervention and multidisciplinary care can decrease the mortality
rate, especially for those who present to ED with the symptom of chest pain.
The strengths of this study are the long observational period and the single-center design, with a
large number of patients. However, the study also has several limitations. First, our center is a large
university teaching hospital, and many patients were already pretreated and secondarily referred by
primary physicians or other hospitals, and many details of the initial treatment are now impossible
to retrieve. Second, there is no standardized and uniform management algorithm for the timing of
surgical intervention when initial treatment fails. Additionally, the treatment by tube thoracostomy for
preoperative management in our cohort of patients was not analyzed.
5. Conclusions
In conclusion, this study demonstrates several important features of ED patients presenting with
empyema. VATS is a safe and effective procedure in all ages, and in stage III thoracic empyema patients.
There is a trend of Viridans streptococci and Mycobacterium tuberculosis as emerging pathogens in the
pathogenesis of empyema. Most importantly, the clinical symptom of chest pain is a reliable factor to
predict an adverse outcome of medical therapy when the patient is first admitted via ED. In particular,
the post-operative outcome may be related to cerebrovascular disease and the serum potassium level.
However, further large-scale studies are warranted to support our observations.
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